To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

Zuzanna Lukasik; Philippe Carron; Casper Webers

doi:10.1016/j.berh.2023.101869

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

Zuzanna Lukasik, Philippe Carron^*, Casper Webers

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

64 Downloads (Pure)

Abstract

The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research.

Original language	English
Article number	101869
Number of pages	17
Journal	Best Practice & Research: Clinical Rheumatology
Volume	37
Issue number	3
Early online date	30 Aug 2023
DOIs	https://doi.org/10.1016/j.berh.2023.101869
Publication status	Published - Sept 2023

Keywords

Axial spondyloarthritis
Biological DMARD
Discontinuation
Remission
Tapering
Therapy

Access to Document

10.1016/j.berh.2023.101869

Full TextFinal published version, 370 KBLicence: Taverne

Cite this

@article{7f6b1cb4a1234d92bf829e052bddbf90,

title = "To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question",

abstract = "The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research.",

keywords = "Axial spondyloarthritis, Biological DMARD, Discontinuation, Remission, Tapering, Therapy",

author = "Zuzanna Lukasik and Philippe Carron and Casper Webers",

year = "2023",

month = sep,

doi = "10.1016/j.berh.2023.101869",

language = "English",

volume = "37",

journal = "Best Practice & Research: Clinical Rheumatology",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023

T2 - That is the question

AU - Lukasik, Zuzanna

AU - Carron, Philippe

AU - Webers, Casper

PY - 2023/9

Y1 - 2023/9

N2 - The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research.

AB - The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research.

KW - Axial spondyloarthritis

KW - Biological DMARD

KW - Discontinuation

KW - Remission

KW - Tapering

KW - Therapy

U2 - 10.1016/j.berh.2023.101869

DO - 10.1016/j.berh.2023.101869

M3 - (Systematic) Review article

VL - 37

JO - Best Practice & Research: Clinical Rheumatology

JF - Best Practice & Research: Clinical Rheumatology

IS - 3

M1 - 101869

ER -

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

Abstract

Keywords

Access to Document

Fingerprint

Cite this